LHRH-agonist versus chemotherapy in premenopausal breast cancer?
Klijn
J G M
JG
Daniel den Hoed Cancer Center (DDHK) and Erasmus University Medical Center Rotterdam (EMCR), Groene Hilledijk 301, PO Box 5201, Rotterdam, The Netherlands. klijn@onch.azr.nl
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D015201:Meta-Analysis as Topic; D017697:Premenopause; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D007987:Gonadotropin-Releasing Hormone